Advanced Memory Research Institute of New Jersey

Toms River, New Jersey 08755

1 studies enrolling now · 17 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease (AD), Alzheimer's Disease, Alzheimer´s Disease, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment, Dementia, Early Preclinical Alzheimer's Disease, Mild Cognitive Impairment (MCI), Preclinical Alzheimer's Disease

Studies at this site

• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) — Completed
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease — Running, not enrolling
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia — Stopped early
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early